Skip to main content

Prevnar 13 Side Effects

Generic name: pneumococcal 13-valent vaccine

Medically reviewed by Last updated on Dec 7, 2023.

Note: This document contains side effect information about pneumococcal 13-valent vaccine. Some dosage forms listed on this page may not apply to the brand name Prevnar 13.

Applies to pneumococcal 13-valent vaccine: intramuscular suspension.

Serious side effects of Prevnar 13

Along with its needed effects, pneumococcal 13-valent vaccine (the active ingredient contained in Prevnar 13) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking pneumococcal 13-valent vaccine:

More common


Incidence not known

Other side effects of Prevnar 13

Some side effects of pneumococcal 13-valent vaccine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common


Incidence not known

For Healthcare Professionals

Applies to pneumococcal 13-valent vaccine: intramuscular suspension.


The most common adverse events were local reactions, irritability, sleep changes, decreased appetite, and fever. Musculoskeletal events were common in adults.[Ref]


Very common (10% or more): Local tenderness (89%), local redness (70%), local swelling (44.5%), induration (32.6%)

Uncommon (0.1% to 1%): Lymphadenopathy localized to the region of the vaccination site

Postmarketing reports: Vaccination site dermatitis, vaccination site urticaria, vaccination site pruritus[Ref]


Uncommon (0.1% to 1%): Hypersensitivity reaction (including face edema, dyspnea, and bronchospasm)

Postmarketing reports: Anaphylactic/anaphylactoid reaction including shock[Ref]

Nervous system

Very common (10% or more): Headache (81.4%)

Uncommon (0.1% to 1%): Seizures (including febrile seizures)

Rare (less than 0.1%): Hypotonic-hyporesponsive episode[Ref]


Very common (10% or more): Fever (43%), fatigue

Uncommon (0.1% to 1%): Crying

Rare (less than 0.1%): Sudden infant death syndrome[Ref]


Very common (10% or more): New muscle pain (82%), aggravated muscle pain (55.9%), new joint pain (41.7%), chills (38.1%) aggravated joint pain (28.6%)[Ref]


Very common (10% or more): Decreased appetite (51%)[Ref]


Very common (10% or more): Irritability (85.6%), increased sleep (71.5%), decreased sleep (45.6%)[Ref]


Very common (10% or more): Vomiting (15%), diarrhea

Uncommon (0.1% to 1%): Gastroenteritis[Ref]


Common (1% to 10%): Hives (urticaria), rash

Postmarketing reports: Flushing, angioedema, erythema multiforme[Ref]


Uncommon (0.1% to 1%): Bronchiolitis, pneumonia[Ref]


1. Cerner Multum, Inc. Australian Product Information.

2. Product Information. Prevnar 13 (pneumococcal 13-valent conjugate vaccine). Apothecon Inc. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.